{"keywords": [{"value": "Drugs (Pharmaceuticals)", "rank": "1", "is_major": "N", "name": "subject"}, {"value": "Valeant Pharmaceuticals International Inc", "rank": "2", "is_major": "N", "name": "organizations"}], "headline": {"kicker": "Breakingviews", "content_kicker": "Breakingviews", "main": "In Trying to Explain Itself, Valeant Muddies the Water"}, "byline": {"original": "By ROBERT CYRAN", "person": [{"rank": 1, "role": "reported", "organization": "", "lastname": "CYRAN", "firstname": "Robert"}]}, "web_url": "http://www.nytimes.com/2015/10/27/business/dealbook/in-trying-to-explain-itself-valeant-muddies-the-water.html", "source": "The New York Times", "subsection_name": "DealBook", "slideshow_credits": null, "type_of_material": "News", "_id": "562e8b0038f0d82f94187c8b", "multimedia": [], "pub_date": "2015-10-27T00:00:00Z", "print_page": null, "section_name": "Business Day", "word_count": "365", "blog": [], "news_desk": "Business", "snippet": "The $39 billion drug company only helped confirm some investor fears about its dealings involving Philidor Rx Services.", "document_type": "article", "abstract": null, "lead_paragraph": "The $39 billion drug company only helped confirm some investor fears about its dealings involving Philidor Rx Services."}